$13.07
+0.20 (+1.55%)
Open$13.02
Previous Close$12.87
Day High$13.20
Day Low$12.68
52W High$16.33
52W Low$1.50
Volume—
Avg Volume2.02M
Market Cap1.21B
P/E Ratio—
EPS$-3.16
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+172.0% upside
Current
$13.07
$13.07
Target
$35.55
$35.55
$27.68
$35.55 avg
$47.36
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 90.24M | 87.45M | 85.26M |
| Net Income | -25,675,790 | -26,182,971 | -21,946,443 |
| Profit Margin | -28.5% | -29.9% | -25.7% |
| EBITDA | -28,181,466 | -22,488,865 | -22,555,214 |
| Free Cash Flow | -17,519,035 | -21,453,021 | -16,827,154 |
| Rev Growth | -3.7% | +3.8% | +9.6% |
| Debt/Equity | 1.03 | 0.84 | 0.93 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |